CSL Behring clinical trial pipeline

6 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 3 with minor changes only.

1. Notable

   Range Finding, Efficacy, and Safety Study of Nebulized CSL787…Range Finding, Efficacy, and Safety Study of Nebulized CSL787 · Non-cystic Fibrosis Bronchiectasis (NCFB)

   Primary completion pushed from Feb 28, 2028 to May 6, 2029

   Also in this update: Enrollment reduced: 450 → 180 participants; Study completion pushed from Mar 28, 2028 to Jun 6, 2029

   CSL Behring·Phase 2· NCT07048262· Registry history of NCT07048262 on ClinicalTrials.gov (opens the registry)

   Oct 19, 2026

2. Notable

   IgPro20 · Secondary Immune Deficiencies Due to Hematologic…IgPro20 · Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

   Primary and study completion pushed from Mar 13, 2029 to Sep 27, 2029

   And 1 more change in the last 30 days

   CSL Behring·Phase 3· NCT07648264· Registry history of NCT07648264 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

3. Notable

   Response on Computed Tomography (CT) Lung Density Decline Rates of…Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years · alpha1 Antitrypsin Deficiency (AATD)

   Recruitment opened

   CSL Behring·Phase 4· NCT07326592· Registry history of NCT07326592 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.